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Abstract
Acute myeloid leukemia patients with normal cytogenetics (CN-AML) account for almost half of AML cases. We aimed to
study the frequency and relationship of a wide range of genes previously reported as mutated in AML (ASXL1, NPM1, FLT3,
TET2, IDH1/2, RUNX1, DNMT3A, NRAS, JAK2, WT1, CBL, SF3B1, TP53, KRAS and MPL) in a series of 84 CN-AML cases. The most
frequently mutated genes in primary cases were NPM1 (60.8%) and FLT3 (50.0%), and in secondary cases ASXL1 (48.5%) and
TET2 (30.3%). We showed that 85% of CN-AML patients have mutations in at least one of ASXL1, NPM1, FLT3, TET2, IDH1/2
and/or RUNX1. Serial samples from 19 MDS/CMML cases that progressed to AML were analyzed for ASXL1/TET2/IDH1/2
mutations; seventeen cases presented mutations of at least one of these genes. However, there was no consistent pattern in
mutation acquisition during disease progression. This report concerns the analysis of the largest number of gene mutations
in CN-AML studied to date, and provides insight into the mutational profile of CN-AML.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease in
terms of karyotype and molecular abnormalities. The discovery of
the classic karyotype abnormalities in AML such as the t(15;17)
has been invaluable in enabling more accurate prognostic
estimates, the development of specific therapies and the molecular
monitoring of disease. However, approximately half of AML
patients have no karyotype abnormality (CN-AML). This group of
AML cases is presumably heterogeneous in all respects, and
molecular monitoring is not possible unless there is an associated
mutation. Recently it has been demonstrated that mutations of
FLT3, NPM1 and CEBPA genes are preferentially found in CN-
AML. [1] Nevertheless many cases do not possess such mutations
and this imposes a severe limitation in understanding their specific
pathophysiology and monitoring disease progression. We have
chosen to study CN-AML with the aim of finding a restricted
panel of genes which are mutated in the majority of cases. In a
series of 84 CN-AML patients, we examined 16 genes with
mutations that had previously been described in cases of CN-AML
(Table S1). [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] The charac-
terisation of cases by the presence or absence of mutations in these
selected genes should allow a molecular dissection of cases of CN-
AML into different biological and prognostic groups, as well as
achieving the long sought after goal of molecular monitoring of
CN-AML.
Design and Methods
Patients
A total of 84 AML patients (mean age 64, range 16 to 86, 23
patients under 60; 52 male, 32 female) with no cytogenetic
abnormalities were recruited for mutational analysis, including 51
primary cases (mean age 60, range 16 to 86, 20 patients under 60;
27 male, 24 female) and 33 cases secondary to either MDS (n= 24)
or CMML (n= 9) (mean age 70, range 51 to 81, 3 patients under
60; 25 male, 8 female). The karyotype was investigated again at
the time of transformation in 31 of the 33 secondary cases, and
found to be normal. An additional 100 cases were investigated for
mutations in ASXL1 from AML patients showing different
karyotypic abnormalities. Some of the cases included in the
present study (16 CN-AML and 51 cases with aberrant
cytogenetics) have been previously analyzed for ASXL1 exon 12
mutations, and results reported elsewhere. [18] All karyotypes
were analyzed by conventional G-banding in at least 30
metaphases. Samples showing inv(16), t(8;21) or t(15;17) at
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karyotype were subjected to confirmation by molecular tech-
niques. This study was approved by the ethics committees of the
institutes involved: the John Radcliffe Hospital (Oxford 06/
Q1606/110), the Royal Bournemouth Hospital (Bournemouth
9991/03/E) and the University of Navarre (Pamplona
IRB00006933); written informed consent was received from all
patients.
Figure 1. Concurrence of mutations in 16 genes analyzed in CN-AML samples. Columns show results for each of the 84 analysed cases.
Solid boxes indicate mutated cases. Grey boxes mark unavailable data. FLT3-ITD mutations are indicated with top-half solid boxes and FLT3-TKD with
bottom-half solid boxes. Similarly, IDH2-R140Q mutations are shown with top-half solid boxes and IDH2-R172K with bottom-half solid boxes.
doi:10.1371/journal.pone.0042334.g001
Table 1. Frequency of mutations in normal karyotype AML samples.
All CN-AML samples (n=84) Primary AML (n=51) Secondary AML (n=33) p value
From MDS (n=24) From CMML (n=9)
ASXL1 18 (21.4%) 2 (3.9%) 10 (41.7%) 6 (66.7%) ,0.0001
NPM1 35 (41.7%) 31 (60.8%) 3 (12.5%) 1 (11.1%) ,0.0001
FLT3 29/81 (35.8%) 24/48 (50%) 4 (16.7%) 1 (11.1%) 0.0019
JAK2 3/60 (5%) 0/44 2/15 (13.3%) 1 (11.1%) 0.0404
TET2 21/81 (25.9%) 11/48 (22.9%) 4 (16.7%) 6 (66.7%) 0.6065
IDH1 10/82 (12.2%) 7/50 (14.0%) 3/23 (13.0%) 0 0.7327
IDH2 10/82 (12.2%) 7/50 (14.0%) 2/23 (8.7%) 1 (11.1%) 0.7327
RUNX1 12/81 (14.8%) 6 (11.8%) 4/21 (19%) 2 (22.2%) 0.3553
CBL 2 (2.4%) 2 (3.9%) 0 0 0.5172
MPL 0 0 0 0 1
TP53 1 (1.2%) 0 1 (4.2%) 0 0.3929
NRAS 5 (6%) 0 3 (12.5%) 2 (22.2%) 0.0077
KRAS 0 0 0 0 1
WT1 3 (3.6%) 3 (5.9%) 0 0 0.2758
DNMT3A 14 (16.7%) 13 (25.5%) 1 (4.2%) 0 0.0068
SF3B1 2 (2.4%) 0 2 (8.3%) 0 0.1515
FLT3 mutations breakdown
FLT3-ITD 27/81 (33.3%) 23/48 (47.9%) 3 (12.5%) 1 (11.1%) 0.0008
FLT3-TKD* 3/81 (3.7%) 2/48 (4.2%) 1 (11.1%) 0 1
IDH2 mutations breakdown
IDH2-R140Q 9/82 (11.0%) 6/50 (12.0%) 2/23 (8.7%) 1 (11.1%) 1
IDH2-R172K 1/82 (1.2%) 1/50 (12.0%) 0 0 1
*One primary AML sample presented concomitant FLT3-ITD and FLT3-TKD mutations.
doi:10.1371/journal.pone.0042334.t001
Mutations in CN-AML
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Table 2. Mutational analysis of serial samples from patients in transformation.
Sample ID
Disease
stage Age
Time from
diagnosis
(+months) Cytogenetics ASXL1 TET2 IDH1 IDH2 Comments
Patient #1 CMML 58 0 46,XY[30] wt M1388I wt wt
AML (+45) 68,XXYYY,+3,+4,
+der(6)x3,+7,+8,
+8,+9,+11,+11,
+12,+13,+17,+19,
+19,+20,+21,+21,
+22[9]/46,XY[41]
wt Q1445X wt wt Previously to
this sampling,
he was
treated with
azacitidine.
After treatment,
the original clone
was replaced with
an aberrant
karyotype
new one, now
harbouring a
different TET2
mutation.
Patient #2 CMML 65 0 46,XY[30] 2242C.CT;
Q748X
+2863A.
AT; T957S
No mut wt wt
AML (+9) 46,XY,i(17)(q10)
[15]/46,XY[15]
2242C.CT;
Q748X
+2863A.AT;
T957S
No mut wt wt
Patient #3 CMML 65 0 47,XY,+8,add
(21)(q22)[30]
1902–1924
delAGAG
GCGGCCA
CCACTGC
CATCG; E63
5RfsX15
2959_2962
het_dupAGAC
+2954_2957
het_dupAAAC
wt wt
AML (+6) 47,XY,+8,add
(21)(q22)[18]/
46,XY,+8,221,
add(21)(q22)[7]
wt wt wt wt Previously to this
sampling he
underwent QT
and BMT. The initial
clone remitted, but
after 5 months a
new clone
appeared,
now including
Monosomy 21,
and having lost
the previously
detected
mutations.
Patient #4 CMML 42 0 45,XY,27[4]/
46,XY[21]
wt wt wt wt
AML (+5) 45,XY,27[47]/
46,XY[3]
wt wt wt wt
Patient #5 MDS 66 0 46,XY[30] 1902–1924del
AGAGGCGGC
CACCACTGCC
ATCG; E635Rfs
X15
wt wt wt
AML (+5) 46,XY[30] 1902–1924del
AGAGGCGGC
CACCACTGC
CATCG; E635
RfsX15
wt wt wt
AML (+10) 46,XY[30] 1902–1924del
AGAGGCGGC
CACCACTGC
CATCG; E635
RfsX15
wt wt wt Sample after
azacitidine
treatment.
Mutations in CN-AML
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Table 2. Cont.
Sample ID
Disease
stage Age
Time from
diagnosis
(+months) Cytogenetics ASXL1 TET2 IDH1 IDH2 Comments
AML (+12) 46,XY[30] 1902–1924del
AGAGGCGGC
CACCACTGC
CATCG; E635
RfsX15
wt wt wt Sample after
azacitidine
treatment.
Patient #6 MDS 72 0 46,XY[30] 1925het_insA;
G643RfsX13
L34F wt wt
AML (+11) 46,XY[30] 1925het_insA;
G643RfsX13
L34F wt wt Additional JAK2,
RUNX1 and NRAS
mutations.
Patient #7 MDS 70 0 46,XY[30] 1934dupG;
G646WfsX12
wt wt wt
MDS (RAEB) (+8) 46,XY[30] 1934dupG;
G646WfsX12
wt wt wt
AML (+15) 46,XY[30] 1934dupG;
G646WfsX12
wt wt wt Additional
NRAS mutation.
Patient #8 MDS 76 0 46,XX[30] 1902–1924del
AGAGGCGGC
CACCACTGC
CATCG E635
RfsX15
wt wt wt
AML (+12) 46,XX[30] 1902–1924del
AGAGGCGGC
CACCACTGCC
ATCG E635
RfsX15
wt R132C wt
Patient #9 MDS (RA) 77 0 46,XX[30] wt Q403X wt wt
CMML (+8) 46,XX[30] 1934dupG
G646WfsX12
Q403X wt wt AML-transformed
at (+40).
Patient #10 MDS (RA) ND 0 46,XX[30] 1934dupG
G646WfsX12
wt wt wt
CMML (+12) 46,XX[30] 1934dupG
G646WfsX12
ND wt wt
Patient #11 MDS 84 0 46,XX[30] 1934dupG
G646WfsX12
L1151P wt wt
MDS (RAEB) (+12) 46,XX[30] 1934dupG
G646WfsX12
L1151P wt wt
Patient #12 MDS 76 0 46,XX[30] 1934dupG
G646WfsX12
Y867H wt R140Q
MDS (RAEB) (+3) 46,XX[30] 1934dupG
G646WfsX12
Y867H wt R140Q Previously to
this sample,
she underwent
one course of AraC.
Patient #13 MDS 64 0 46,XX[30] 1934dupG wt wt R140Q
MDS (RAEB) (+12) 46,XX[30] 1934dupG wt wt R140Q
Patient #14 MDS 79 (+20) 46,XX,del(5)
(q15:q33)[30]
1934dupG
G646WfsX12
S794X wt wt
MDS (RAEB) (+53) 46,XX,del(5)
(q15:q33)[30]
1934dupG
G646WfsX12
S794X wt wt
Patient #15 MDS 80 0 46,XX[30] wt wt wt wt
MDS (+1) 46,XX[30] wt wt wt wt
AML (+2) 46,XX[30] 2893C.
C/T; R965X
wt wt wt Non mutated
for any of the
15 other genes
included in this
study.
Mutations in CN-AML
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DNA sequencing and analysis
Genomic DNA was isolated from patient bone marrow or
peripheral blood samples. Primers and PCR conditions for the 16
genes analyzed are detailed in Table S2. Relevant regions were
selected for analysis (Table S2): exons 12 of ASXL1
(NM_015338.5) and NPM1 (NM_002520), exons 11 and 17 of
FLT3 (NM_004119), exon 14 of JAK2 (NM_004972), entire
coding region of TET2 (NM_001127208.2), Exons 4 of IDH1
(NM_005896) and IDH2 (NM_002168), exons 3 to 8 of RUNX1
(NM_001001890), exons 7–9 of CBL (NM_005188), exons 9 and
10 of MPL (NM_005373), exons 3 to 9 of TP53 (NM_000546),
exons 2 and 3 of NRAS (NM_002524.4) and KRAS (NM_033360),
Exons 4 to 9 of WT1 (NM_024426), exons 7 to 23 of DNMT3A
(NM_022552) and exons 12 to 16 of SF3B1 (NM_012433.2). PCR
was performed using ThermoStart PCR Master Mix (Thermo
Fisher Scientific), following the manufacturer’s protocol. PCR
products were purified and bidirectionally sequenced using the
BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA, USA) and an ABI 3100 Genetic Analyzer.
Sequence data were analyzed using Mutation Surveyor V3.25
(Softgenetics, State College, PA, USA). Two sided Fisher’s exact
test was performed to compare mutation frequencies in primary
versus secondary cases, and in the analysis of cooperating
mutations.
Results and Discussion
A total of 84 CN-AML patients were recruited for mutational
analysis, including 51 primary cases and 33 cases secondary to
either MDS (n= 24) or CMML (n= 9). The 16 genes analyzed
were: ASXL1, NPM1, FLT3, TET2, IDH1, IDH2, RUNX1,
DNMT3A, NRAS, JAK2, WT1, CBL, SF3B1, TP53, KRAS and
MPL. The regions analysed for each gene are detailed in Table S2.
The frequencies of mutation are shown in Table 1. The most
frequently mutated genes in primary cases were NPM1 (60.8%)
and FLT3 (50.0%), and in secondary cases ASXL1 (48.5%) and
TET2 (30.3%).
An analysis of the mutations occurring in more than 10% of
cases revealed statistically significant associations (Figure 1, Table
S3). In agreement with previous reports, FLT3 and DNMT3A
mutations were significantly associated with NPM1 mutations, [12]
whereas patients with ASXL1 mutations had significantly lower
incidence of NPM1 and DNMT3A mutations. [8,9] IDH1 and
IDH2 mutations were mutually exclusive. With the exception of
one patient, no cases with IDH1/2 mutation also had a TET2
mutation. IDH1 and IDH2 mutations were less frequent in TET2-
mutated than in TET2-wt patients, and this has been reported
before. [19,20] Concurrence of IDH1/2 and ASXL1mutations was
also a relatively infrequent event in our patient cohort (Figure 1).
This observation is in agreement with a report on a series of 63
AML secondary to MPN cases. [3]
Table 2. Cont.
Sample ID
Disease
stage Age
Time from
diagnosis
(+months) Cytogenetics ASXL1 TET2 IDH1 IDH2 Comments
Patient #16 MDS 71 0 45,XX,add(3)(p14),
del(5)(q13:q33),
add(7)(q22),+8,
212,213,2
16,i(20)(q10),
+mar1[18]/
48,XX,+1,del(5)
(q13:q33),
add(7)(q22),+8,
212,213,
+mar1,+mar2[7]
wt wt wt wt
MDS (RAEB) (+6) 45,XX,add(3)(p14),
del(5)(q13:q33),
add(7)(q22),+8,
212,213,216,
i(20)(q10),
+mar1[18]/48,XX,
+1,del(5)(q13:q33),
add(7)(q22),+8,212,
213,+mar1,+mar2[7]
wt wt wt wt Later (+10), she
developed four
additional complex
karyotype clones.
Patient #17 MDS (RAEB) 65 0 46,XY[30] 1863–1873del
L622RfsX9
wt wt wt
AML (+10) 46,XY[30] 1863–1873del
L622RfsX9
wt wt wt Additional FLT3
mutation (ITD)
Patient #18 MDS (RA) ND 0 45,XX,27[30] 1934dupG
G646WfsX12
(same mutation
as M871)
wt wt wt
AML (+8) 45,XX,27[30] 1934dupG
G646WfsX12
wt wt wt
Patient #19 MDS ND 0 46,XX[30] wt wt wt R140Q
MDS (RAEB) (+9) 46,XX[30] wt wt wt R140Q
doi:10.1371/journal.pone.0042334.t002
Mutations in CN-AML
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ASXL1 mutations were significantly more frequent in secondary
AML compared to de novo AML cases (primary cases: 2/51, 3.9%;
secondary to MDS/CMML: 16/33, 48.5%, p,0.0001). We have
previously reported a high prevalence of ASXL1 mutations in
advanced MDS. [18] NPM1, FLT3, and DNMT3A mutations were
significantly more common in primary CN-AML than in
secondary AML cases (Table 1). NRAS, JAK2, SF3B1 and TP53
mutations were exclusively present in secondary AML samples
(Table 1). Only 9.5% of the samples analyzed (8/84, 6 de novo and
2 post-MDS cases) showed no mutation in any of the genes tested.
When considering only the ASXL1, NPM1, FLT3, TET2, IDH1/2
and RUNX1 gene analysis, 88% of de novo CN-AML included in
this series presented at least one molecular marker. For secondary
cases, 85% of patients carried mutations in at least one of these 7
genes.
Recent reports showed that DNMT3A mutations are associated
with a poor outcome in AML, [21,22] and that the location of the
mutations could have an impact in age-related risk classification.
[23] It is worth noting that in our series, DNMT3A was not found
as a sole mutation suggesting that additional aberrations are
needed to sustain leukemogenic development.
Approximately 70% of CN-AML cases secondary to either
MDS or CMML presented mutations in at least one of ASXL1,
TET2, IDH1 or IDH2 genes. Therefore, we chose to assess the
presence and chronology of ASXL1, TET2 and IDH1/2
mutational events, in order to investigate whether they could
have a role in disease development or evolution. We studied 15
MDS and 4 CMML cases that progressed to AML, for which at
least two samples at different time-points were available.
Remarkably, with the exception of two patients all of them
possessed at least one gene mutation at some stage of the disease.
The majority showed the same mutations at early and later stages
of the disease, except one patient who developed an IDH1
mutation at transformation, a second patient with a TET2
mutation who acquired an additional ASXL1 mutation at
transformation, and another patient who developed a nonsense
mutation of ASXL1 at AML stage, and showed rapid disease
evolution (Table 2). On the basis of this study we therefore did not
find any consistent patterns in mutation acquisition. A sensitive
mutation analysis (such as allele-specific PCR) at early stages of
AML in future studies could help clarify whether the mutations
found in cases from later stage AML were already present as a
minor pre-existing clone at the earlier stage, and if so, how it
evolved as the disease progressed to AML.
In order to investigate whether the observed low incidence of
ASXL1 mutations is a specific characteristic of karyotypically
normal de novo cases, or is a common feature of other subtypes of
primary AML, we screened an additional cohort of 100 primary
AML, including the most common karyotypic subgroups. Overall,
only 8 out of 100 cases showed nonsense or frameshift mutations
(8%) (Table S4), confirming that ASXL1 mutations are less
common in primary AML than in secondary AML.
This report concerns the analysis of the largest number of gene
mutations in CN-AML studied to date. Our results show that 85%
of CN-AML patients have mutations in one or more of 7 selected
genes (ASXL1, NPM1, FLT3, TET2, IDH1/2 and RUNX1). This
finding will facilitate further analysis of this important group of
patients by enabling CN-AML patients to be subdivided into
groups with common mutation patterns. Detailed studies of the
CN-AML subgroups in regard to their hematological features,
prognosis, disease progression and treatment response will now be
facilitated.
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Table S1 Relevant literature on mutations of AML patients.
ND=not done. CN= cytogenetically normal. MPN=myelopro-
liferative neoplasm. Yo= years old. CBF= core binding factor.
APL= acute promyelocytic leukemia.
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Table S2 Primers and PCR conditions. PCR was performed
using ThermoStart PCR Master Mix (Thermo Fisher Scientific),
following the manufacturer’s protocol, 35 cycles, unless otherwise
stated, using indicated annealing temperature. The same primers
were used for Sanger sequencing unless otherwise stated.
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Table S3 Double-sided Fisher’s exact test analysis of coopera-
tion between most frequent mutations in normal karyotype AML
samples.
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Table S4 ASXL1 mutations in 100 de novo AML cases with
aberrant cytogenetics.
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